Clinical pharmacological study of TM5509 -Clinical pharmacological study in male mild obesity subjects (additional test)
- Conditions
- Recover of hematogenesis after cord blood transplantation
- Registration Number
- JPRN-UMIN000020337
- Lead Sponsor
- Tohoku university school of medicine, molecular medicine and therapy, Toshio Miyata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 10
Not provided
1.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2.Known hypersensitivity to some drugs and foods 3.More than grade 1 in liver function disorders 4.Treatment by other doctors (included supplement) within 14 days before screening 5.Treatment with any investigational compound within 120 days before screening 6.History of TM5509 administration 7.History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 8.Smoking status and treatment with anti-nicotine agents 9.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 10.Abuse of alcohol or drugs (included past history) 11.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 12.Somebody who are directed by principle investigator and employees in Hamamatsu University hospital 13.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacodynamics of TM5509
- Secondary Outcome Measures
Name Time Method Safety and Pharmacokinetics of TM5509